Clinical trials
Phase 1 Liposarcoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2024 | 5 |
| 2025 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Recruiting | 6 |
| Active, not recruiting | 4 |
| Terminated | 3 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Baylor College of Medicine | 4 |
| National Cancer Institute (NCI) | 2 |
| OHSU Knight Cancer Institute | 2 |
| Seattle Children's Hospital | 2 |
| Valerio Therapeutics | 2 |
| Dana-Farber Cancer Institute | 1 |
| Epkin | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Fred Hutchinson Cancer Center | 1 |
| Heidelberg University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Liposarcoma | 29 |
| Sarcoma | 15 |
| Leiomyosarcoma | 12 |
| Rhabdomyosarcoma | 9 |
| Histiocytoma, Malignant Fibrous | 8 |
| Sarcoma, Synovial | 8 |
| Endodermal Sinus Tumor | 6 |
| Fibrosarcoma | 6 |
| Hemangiosarcoma | 6 |
| Dermatofibrosarcoma | 5 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.